Eko Raises $65 Million in Series C Funding to Close the Gap Between Virtual and In-Person Heart and Lung Care

Nov 09, 2020•over 4 years ago

Amount Raised

$65 Million

Round Type

series c

Description

Eko, a cardiopulmonary digital health company, today announced $65 million in Series C funding led by Highland Capital Partners and Questa Capital, with participation from Artis Ventures, DigiTx Partners, NTTVC, 3M Ventures, and other new and existing investors. The new funding will be used to expand in-clinic use of the company’s platform of telehealth and AI algorithms for disease screening, and to launch a monitoring program for cardiopulmonary patients at home.

Company Information

Company

Eko

About

Now there’s real-world data to suggest that the company has made progress, and it has secured a $30M extension to its earlier C round to continue its work. But the company has also been tweaking some FDA approved clinical support algorithms. (A company earns this when it demonstrates that its tech is similar to what is already out there). But so far, the company has focused on devices and clinical tools. As COO Jason Bellet told TechCrunch after the closing of Eko’s series A round in 2019, the company was really going after “screening for structural heart diseases and heart failure.”Heart failure affects about 7 million people in the US, and is expected to reach 8 million by 2030. The company has made progress on that front, but has not yet received FDA clearance to use the algorithm clinically. That extension will allow the company to support further commercialization efforts and develop new products, said Landgraf.

FundzWatch™ Score

Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech